Viking Therapeutics Inc (VKTX):企業の財務・戦略的SWOT分析

◆英語タイトル:Viking Therapeutics Inc (VKTX) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C14733
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Viking Therapeutics Inc (Viking Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. The company’s lead clinical program product candidate include VK5211, an orally available, non-steroidal selective androgen receptor modulator developed for the treatment of lean body mass loss in patients who have undergone hip fracture surgery. Its other pipeline product candidates include VK0214 for the treatment of orphan indication, a rare X-linked inherited neurological disorder; VK2809 developed for orally available tissue and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease; and VK0612, an inhibitor of fructose -1,6-biphosphatase for type 2 diabetes. Viking Therapeutics is headquartered in San Diego, California, the US.

Viking Therapeutics Inc Key Recent Developments

Nov 07,2018: Viking Therapeutics reports third quarter 2018 financial results and provides corporate update
Sep 25,2018: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol
Aug 28,2018: Viking Therapeutics to Participate in Upcoming Investor Conferences
Aug 09,2018: Viking Therapeutics reports second quarter 2018 financial results and provides corporate update

This comprehensive SWOT profile of Viking Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Viking Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Viking Therapeutics Inc – Key Information
Viking Therapeutics Inc – Overview
Viking Therapeutics Inc – Key Employees
Viking Therapeutics Inc – Key Employee Biographies
Viking Therapeutics Inc – Key Operational Heads
Viking Therapeutics Inc – Major Products and Services
Viking Therapeutics Inc – History
Viking Therapeutics Inc – Company Statement
Viking Therapeutics Inc – Locations And Subsidiaries
Viking Therapeutics Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Viking Therapeutics Inc – Business Description
Viking Therapeutics Inc – Corporate Strategy
Viking Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Viking Therapeutics Inc – Strengths
Viking Therapeutics Inc – Weaknesses
Viking Therapeutics Inc – Opportunities
Viking Therapeutics Inc – Threats
Viking Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Viking Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Viking Therapeutics Inc, Key Information
Viking Therapeutics Inc, Key Ratios
Viking Therapeutics Inc, Share Data
Viking Therapeutics Inc, Major Products and Services
Viking Therapeutics Inc, History
Viking Therapeutics Inc, Key Employees
Viking Therapeutics Inc, Key Employee Biographies
Viking Therapeutics Inc, Key Operational Heads
Viking Therapeutics Inc, Other Locations
Viking Therapeutics Inc, Subsidiaries
Viking Therapeutics Inc, Key Manufacturing facilities
Viking Therapeutics Inc, Key Competitors
Viking Therapeutics Inc, SWOT Analysis
Viking Therapeutics Inc, Ratios based on current share price
Viking Therapeutics Inc, Annual Ratios
Viking Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Viking Therapeutics Inc, Performance Chart
Viking Therapeutics Inc, Ratio Charts

★海外企業調査レポート[Viking Therapeutics Inc (VKTX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Contact Energy Ltd (CEN):石油・ガス:M&Aディール及び事業提携情報
    Summary Contact Energy Ltd (Contact Energy) is an energy company that generates electricity and sells electricity, natural gas and liquefied petroleum gas to customers. It generates electricity from various sources of energy including thermal, hydro and geothermal sources of energy. It supplies elec …
  • Anthem, Inc.:企業の戦略・SWOT・財務情報
    Anthem, Inc. - Strategy, SWOT and Corporate Finance Report Summary Anthem, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Barry-Wehmiller Companies, Inc.:企業の戦略・SWOT・財務情報
    Barry-Wehmiller Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Barry-Wehmiller Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Kenya Electricity Generating Co Ltd (KGEN):電力:M&Aディール及び事業提携情報
    Summary Kenya Electricity Generating Co Ltd (KenGen) is an electricity generation utility. It produces power from hydro, geothermal, thermal, and wind sources. Under power purchase agreements, the company sells power to customers on wholesale basis. Kenya Power and Lighting Company Limited is the au …
  • DIA Imaging Analysis Ltd:医療機器:M&Aディール及び事業提携情報
    Summary DIA Imaging Analysis Ltd (DIA Imaging Analysis), formerly DiACardio Ltd is a provider of medical imaging solutions. The company’s products comprise LVivo SWM, LVivo EF, and LVivo Strain. Its LVivo SWM is a fully automated echo device or PACS systems. DiACardio’s LVivo platform comprises tool …
  • Mediq NV:企業の戦略的SWOT分析
    Mediq NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • FirstGroup plc (FGP):企業の財務・戦略的SWOT分析
    FirstGroup plc (FGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Datang International Power Generation Co Ltd (991)-エネルギー分野:企業M&A・提携分析
    Summary Datang International Power Generation Company Limited (Datang Power), a subsidiary of China Datang Corporation, is an independent power generation company. It develops power plants; produces and distributes electricity; and sells heat. The company generates electricity from coal-fired genera …
  • Mitobridge Inc-製薬・医療分野:企業M&A・提携分析
    Summary Mitobridge Inc (Mitobridge), formerly Mitokyne, Inc. is a drug development company that discovers and develops small molecule therapeutics. The company offers products that enhance the mitochondrial functions. It develops therapies for rare diseases and then expand into more common diseases. …
  • Tan Viet Securities Joint Stock Company:企業の戦略的SWOT分析
    Tan Viet Securities Joint Stock Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Dentsu Inc (4324):企業の財務・戦略的SWOT分析
    Dentsu Inc (4324) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • CryoTherapeutics Gmbh-医療機器分野:企業M&A・提携分析
    Summary CryoTherapeutics GmbH (CryoTherapeutics) is a medical equipment company that offers systemic drug based approach in combination with a localised device-based therapy. The company’s proprietary cryotherapy system is used for the treatment of coronary artery disease that causes heart attacks. …
  • Swisscom, Ltd.:企業のM&A・事業提携・投資動向
    Swisscom, Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Swisscom, Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Pan Malaysia Holdings Berhad:企業の戦略・SWOT・財務分析
    Pan Malaysia Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary Pan Malaysia Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Blue Dolphin Energy Co (BDCO):企業の財務・戦略的SWOT分析
    Summary Blue Dolphin Energy Co (Blue Dolphin) operates as an oil and gas company that refines and markets petroleum products. The company own and operate pipeline assets and have leasehold interests in oil and gas properties. It also acquires, develops and explores oil and gas properties. Blue Dolph …
  • Coresa Sa
    Coresa Sa - Strategy, SWOT and Corporate Finance Report Summary Coresa Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • PharmaEssentia Corp (6446):製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaEssentia Corp (PharmaEssentia) is a developer of therapeutic products for the treatment of human diseases. The company’s pipeline product includes P1101, a new generation PEG-Interferon-alpha-2b which is developed using PEGylation technology platform. Its pegylation technology platform …
  • Juniper Networks, Inc.:企業の戦略・SWOT・財務情報
    Juniper Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary Juniper Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Xtract Resources Plc (XTR):企業の財務・戦略的SWOT分析
    Summary Xtract Resources Plc (Xtract Resources), formerly Xtract Energy plc is a mining and mineral exploration and development company that offers mineral resources. The company acquires, explores, manages, operates, produces, mines, extracts, and develops gold and mineral resource deposit properti …
  • ONEOK Partners LP (OKS)-石油・ガス分野:企業M&A・提携分析
    Summary ONEOK Partners, L.P. (ONEOK Partners), a subsidiary of Oneok, Inc., is a midstream energy company. The company carries out gathering, processing, and storage and transportation of natural gas. It operates through master limited partnerships. ONEK Partners owns natural gas liquids (NGL) syste …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆